We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

e-Therapeutics plc (ETX) Ordinary 0.1p

Sell:8.60p Buy:9.95p 0 Change: No change
Market closed Prices as at close on 26 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8.60p
Buy:9.95p
Change: No change
Market closed Prices as at close on 26 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8.60p
Buy:9.95p
Change: No change
Market closed Prices as at close on 26 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.

Contact details

Address:
Floor 4
4 Kingdom Street, Paddington Central
LONDON
W2 6BD
United Kingdom
Telephone:
+44 (020) 45518888
Website:
https://www.etherapeutics.co.uk/

Important dates

Future events
There are no future events available.
Past events
Interim results 26 October 2023 26/10/23
AGM 18 July 2023 18/07/23
Annual report 11 May 2023 11/05/23
Final results 04 May 2023 04/05/23

General stock information

EPIC:
ETX
ISIN:
GB00B2823H99
Market cap:
£56.10 million
Shares in issue:
584.34 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Ali Mortazavi
    Chief Executive Officer, Executive Director
  • Michael Bretherton
    Interim Chief Financial Officer, Non-Executive Director
  • Timothy Bretherton
    Director of Finance and Operations
  • Laura Roca-alonso
    Chief Operating Officer
  • Alan Whitmore
    Chief Scientific Officer
  • Alison Gallafent
    Chief Intellectual Property Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.